Mattes Glenn R. 4
4 · TFF Pharmaceuticals, Inc. · Filed Jan 20, 2021
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2021-01-15$2.50/sh+40,000$100,000→ 50,000 total - Sale
Common Stock
2021-01-15$17.51/sh−40,000$700,400→ 10,000 total - Sale
Common Stock
2020-09-25$17.00/sh−3,000$51,000→ 7,000 total(indirect: By Spouse) - Exercise/Conversion
Stock Options (Right to Buy)
2021-01-15−40,000→ 1,034,227 totalExercise: $2.50From: 2019-05-01Exp: 2028-05-01→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]200,000 shares of the option vested and became exercisable on May 1, 2019.